SecBot SecBot
424B5 ·Filed Sep 10, 2026

AXGN

Axogen, Inc.
MIXED
Impact 6/10
Horizonweeks Processed2mo ago SEC0001628280-26-061394
Actionable Insight ◆ Mixed

The 10% discount to market and 9.1% share dilution create near-term selling pressure, but the acquisition of BioCircuit's NerveTape/ConformaWrap products strengthens the peripheral nerve repair portfolio. Watch for Q4 2026 closing of the BioCircuit deal and any updates on the conditions (IP license consent, convertible note conversion, electronics spin-out). If the acquisition closes, the combined product line could drive revenue acceleration; if it fails, the $195.5M in cash provides a strong balance sheet for other uses.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$42.16
T+0 close · Sep 10, 2026 · via day close
Latest settled
−14.30%
T+20 · $36.13 · next T+60 in 20d
Vs SPY
−16.17%
α at T+20
Latest observation
+41.35%
T+46 · FF3 residual α
  1. T+0 · Sep 11 $42.16entry
  2. T+1 · 2mo ago +3.84%α +4.29% · $43.78
  3. T+5 · 2mo ago +4.91%α +5.13% · $44.23
  4. T+20 · 6w ago −14.30%α −16.17% · $36.13
  5. T+46 · todayOpen
  6. T+60 · in 20d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axogen is conducting a $208.7M underwritten public offering of 4.91M shares at $42.50/share (a ~10% discount to the $47.27 close), with an underwriter option for an additional 736,500 shares. Net proceeds of ~$195.5M are earmarked to fund the $200M cash acquisition of BioCircuit Technologies (NerveTape/ConformaWrap products), expected to close in Q4 2026. The offering is not contingent on the acquisition closing. Existing shareholders face immediate dilution of $34.92/share (82% of offering price). The combination of a dilutive equity offering tied to a transformative acquisition creates a mixed signal, the acquisition expands the product portfolio but the 9.1% share increase and 10% discount to market are near-term headwinds.

Key Facts

  • 4,910,000 shares offered at $42.50/share, a ~10% discount to the $47.27 prior close
  • Gross proceeds of $208,675,000; net proceeds ~$195.5M after underwriting discounts and expenses
  • Underwriters have a 30-day option to purchase up to an additional 736,500 shares
  • Net proceeds intended to fund the $200M cash acquisition of BioCircuit Technologies (NerveTape/ConformaWrap)
  • BioCircuit Acquisition expected to close in Q4 2026; offering not conditioned on its completion
  • Immediate dilution of $34.92 per share for new investors (82% of offering price)
  • Pro forma cash increases from $94.6M to $290M; total shareholders' equity rises from $256.3M to $451.7M
  • 90-day lock-up agreements for directors and executive officers
  • Joint book-running managers: BofA Securities, Jefferies, Wells Fargo Securities; additional bookrunner: Mizuho

Financial Impact

~$195.5M net proceeds raised; $200M cash acquisition of BioCircuit; immediate dilution of $34.92/share (82% of offering price) for new investors

dilutioncashshare countacquisition funding

Risk Factors

  • BioCircuit Acquisition may not close on terms or timeline, leaving proceeds deployed suboptimally
  • Integration of BioCircuit may be difficult, costly, or time-consuming
  • Substantial dilution (82% of offering price) may pressure stock near term
  • Future equity issuances could further dilute shareholders
  • No dividends expected; return depends on stock appreciation

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (AXGN), Batch item 10001628280-26-061394
Document: axgnexfilingfees.htm0001628280-26-061394
Document: 0001628280-26-061394-index-headers.html0001628280-26-061394
Document: 0001628280-26-061394-index.html0001628280-26-061394
Document: 0001628280-26-061394.txt0001628280-26-061394
424B5 Filing (AXGN), Batch item 60001628280-26-061394

Track record

19 reports on AXGN

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +32.04% at T+20 after the Oct 1, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $55.78 Now $55.38 +0.72% settles Dec 15
  2. Nov 9, 20267d ago 8-K Bullish 5/10 Entry $50.64 Now $55.38 +9.36% settles Dec 8
  3. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $51.35 Now $55.38 +7.85% settles Dec 3
  4. Oct 28, 202619d ago 8-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $49.25 Now $55.38 +12.45% settles Nov 25
  6. Oct 2, 20266w ago SC 13G Neutral 4/10 Entry $37.22 to $49.37 Now $55.38 +48.79% ▲ +32.64% +35.11% vs SPY
  7. Oct 1, 20266w ago 8-K Bullish 6/10 Entry $37.39 to $49.37 Now $55.38 +48.11% ▲ +32.04% +33.85% vs SPY
  8. Oct 1, 20266w ago Press Release Bullish 6/10 Entry $37.39 to $49.37 Now $55.38 +48.11% ▲ +32.04% +33.85% vs SPY
  9. Sep 10, 20269w ago 424B5 Mixed 6/10 Viewing Entry $42.16 to $36.13 Now $55.38 +31.36% ▼ −14.30% −16.17% vs SPY
  10. Sep 10, 20269w ago 8-K Bullish 7/10 Entry $41.85 to $36.18 Now $55.38 +32.33% ▼ −13.55% −15.67% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 10, 2026